Patents Assigned to Ribi ImmunoChem Research, Inc.
  • Pyridine soluble extract of a microorganism
    Patent number: 4505903
    Abstract: A pharmaceutical composition is disclosed comprising a purified pyridine-soluble extract obtained from a microorganism which contains between about 7 and 20% by weight of protein, between about 10 and 16% by weight of sugar, and between about 35 and 55% by weight of fatty acids which when combined with cell wall skeleton and trehalose dimycolate in a pharmaceutically acceptable medium is useful as an anti-animal tumor agent in the treatment of animals.
    Type: Grant
    Filed: April 17, 1984
    Date of Patent: March 19, 1985
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventor: John L. Cantrell
  • Pyridine soluble extract of a microorganism
    Patent number: 4504473
    Abstract: A pharmaceutical composition is disclosed comprising a purified pyridine-soluble extract obtained from microorganism which contains between about 7 and 20% by weight of protein, between about 10 and 16% by weight of sugar, and between about 35 and 55% by weight of fatty acids which when combined with trehalose dimycolate and an acetone precipitated by-product of endotoxic glycol lipids extracted with chloroform-methanol in a pharmaceutically acceptable medium is useful as an anti-animal tumor agent in the treatment of animals.
    Type: Grant
    Filed: April 17, 1984
    Date of Patent: March 12, 1985
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventor: John L. Cantrell
  • Pyridine soluble extract of a microorganism
    Patent number: 4503048
    Abstract: A method of producing a purified pyridine-soluble extract of a microorganism is disclosed which contains between about 7 and 20% by weight of protein, between about 10 and 16% by weight of sugar, and between about 35 and 55% by weight of fatty acids. The extract when combined with cell wall skeleton in a pharmaceutically acceptable medium is useful as an anti-tumor agent in the treatment of animals.
    Type: Grant
    Filed: July 18, 1984
    Date of Patent: March 5, 1985
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventor: John L. Cantrell
  • Refined detoxified endotoxin product
    Patent number: 4436728
    Abstract: A pharmaceutical composition comprising refined detoxified endotoxin, cell wall skeleton and trehalose dimycolate is disclosed which is effective for the treatment of cancerous tumors. Methods of using the composition for these purposes are also disclosed.
    Type: Grant
    Filed: May 26, 1982
    Date of Patent: March 13, 1984
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventors: Edgar E. Ribi, Steven M. Schwartzman, John L. Cantrell
  • Refined detoxified endotoxin product
    Patent number: 4436727
    Abstract: A refined detoxified endotoxin (RDE) product is disclosed which, when combined with cell wall skeleton (CWS), results in a composition useful for the treatment of cancerous tumors. Methods of making RDE as well as methods of using the combination of RDE and CWS are also disclosed.
    Type: Grant
    Filed: May 26, 1982
    Date of Patent: March 13, 1984
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventor: Edgar E. Ribi
  • Refined detoxified endotoxin product
    Patent number: 4435386
    Abstract: A pharmaceutical composition comprising refined detoxified endotoxin, trehalose dimycolate, and an acetone precipitated by-product of endotoxic glycolipids extracted with chloroform-methanol (ACP) is disclosed which is useful for the treatment of cancerous tumors. Methods of using the composition for these purposes are also disclosed.
    Type: Grant
    Filed: May 26, 1982
    Date of Patent: March 6, 1984
    Assignee: Ribi ImmunoChem Research, Inc.
    Inventors: Edgar E. Ribi, Cantrell John L.